All Studies Meta Analysis Recent:

A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate Coronavirus disease 2019 (COVID-19)

Chen et al., PLoS ONE, doi:10.1371/journal.pone.0242763, NCT04384380

Jul 2020

Post
Facebook

Source PDF All Meta

HCQ for COVID-19

1st treatment shown to reduce risk in March 2020

^*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.

Lower risk for mortality, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine complementary and synergistic treatments. ^* >10% efficacy in meta analysis with ≥3 clinical studies.

4,000+ studies for 60+ treatments. c19hcq.org

2 very small studies with hospitalized patients in Taiwan.

RCT with 21 treatment and 12 SOC patients. No mortality, or serious adverse effects. Median time to negative RNA 5 days versus 10 days SOC, p=0.4. Risk of PCR+ at day 14, RR 0.76, p = 0.71.

This paper also reports on a small retrospective study with 12 of 28 HCQ patients and 5 of 9 in the control group being PCR- at day 14, RR 1.29, p = 0.7.

Although the viral clearance result is not statistically significant, it is consistent with the significant 19% improved viral clearance [10‑28%] from meta analysis of the 45 viral clearance results to date.

Important missing comments or errors? Let us know.

risk of no viral clearance, 24.0% lower, RR 0.76, p = 0.71, treatment 4 of 21 (19.0%), control 3 of 12 (25.0%), NNT 17, day 14.

median time to PCR-, 50.0% lower, relative time 0.50, p = 0.40, treatment 21, control 12.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Chen et al., 10 Jul 2020, Randomized Controlled Trial, Taiwan, peer-reviewed, 19 authors, study period 1 April, 2020 - 31 May, 2020, trial NCT04384380 (history).

This Paper HCQ All

A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)

Cheng-Pin Chen, Yi-Chun Lin, Tsung-Chia Chen, Ting-Yu Tseng, Hon-Lai Wong, Cheng-Yu Kuo, Wu-Pu Lin, Sz-Rung Huang, Wei-Yao Wang, Jia-Hung Liao, Chung-Shin Liao, Yuan-Pin Hung, Tse-Hung Lin, Tz-Yan Chang, Chin-Fu Hsiao, Yi-Wen Huang, Wei-Sheng Chung, Chien-Yu Cheng, Shu-Hsing Cheng

PLOS ONE, doi:10.1371/journal.pone.0242763

Objective In this study, we evaluated the efficacy of hydroxychloroquine (HCQ) against coronavirus disease 2019 (COVID-19) via a randomized controlled trial (RCT) and a retrospective study. Methods Subjects admitted to 11 designated public hospitals in Taiwan between April 1 and May 31, 2020, with COVID-19 diagnosis confirmed by pharyngeal real-time RT-PCR for SARS-CoV-2, were randomized at a 2:1 ratio and stratified by mild or moderate illness. HCQ (400 mg

Author Contributions Conceptualization: Cheng-Pin Chen, Yi-Chun Lin, Chien-Yu Cheng, Shu-Hsing Cheng. Data curation: Yi-Chun Lin, Chin-Fu Hsiao, Shu-Hsing Cheng. Formal analysis: Cheng-Pin Chen, Yi-Chun Lin, Chin-Fu Hsiao, Chien-Yu Cheng, Shu-Hsing Cheng. Funding acquisition: Shu-Hsing Cheng. Investigation: Cheng-Pin Chen, Tsung-Chia Chen, Ting-Yu Tseng, Hon-Lai Wong, Cheng-Yu Kuo, Wu-Pu Lin, Sz-Rung Huang, Wei-Yao Wang, Jia-Hung Liao, Chung-Shin Liao, Yuan-Pin Hung, Tse-Hung Lin, Tz-Yan Chang, Yi-Wen Huang, Wei-Sheng Chung, Chien-Yu Cheng. Methodology: Chin-Fu Hsiao, Chien-Yu Cheng. Supervision: Yi-Wen Huang, Wei-Sheng Chung. Writing -original draft: Cheng-Pin Chen, Yi-Chun Lin. Writing -review & editing: Chien-Yu Cheng, Shu-Hsing Cheng.

References

Arshada, Kilgore, Chaudhry, Jacobsen, Wang et al., Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, J Infect Dis, doi:10.1016/j.ijid.2020.06.099.

Borba, Val, Sampaio, Alexandre, Melo et al., Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.8857

Caly, Druce, Catton, Jans, Wagsta, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104787

Cao, Wang, Liu, Wang, Fan, A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19, New Engl J Med, doi:10.1056/NEJMoa2001282

Chen, Hu, Zhang, Jiang, Han et al., Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, doi:10.1001/jama.2020.22240

Chen, Liu, Liu, Liu, Xu et al., A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19), Zhejiang Da Xue Xue Bao Yi Xue Ban, doi:10.3785/j.issn.1008-9292.2020.03.03

Cheng, Chang, Chiang, Chien, Cheng et al., First case of coronavirus disease 2019 (COVID-19) pneumonia in Taiwan, J Formos Med Assoc, doi:10.1016/j.jfma.2020.02.007

Cheng, Li, Chen, Lin, Liu et al., Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan, J Microbiol Infect Immunol, doi:10.1016/j.jmii.2020.03.032

Food, Drug, for use of chloroquine phosphate or hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of 2019 Coronavirus Disease

Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc Jpn Acad Ser B Phys Biol Sci, doi:10.2183/pjab.93.027

Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, doi:10.5582/bst.2020.01047

Gautret, Lagier, Parola, Hoang, Meddeb et al., Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101663

Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949

Geleris, Sun, Platt, Zucker, Baldwin et al., Observational study of hydroxychloroquine in hospitalized patients with Covid-19, New Engl J Med, doi:10.1056/NEJMoa2012410

Health, Welfare, Huang, Chen, Shin et al., Naming the coronavirus disease (COVID-19) and the viral that caused it

Holshue, Debolt, Lindquist, Lofy, Wiesman et al., First case of 2019 novel coronavirus in the United States, N Engl J Med, doi:10.1056/NEJMoa2001191

Mehra, Desai, Kuy, Henry, Patel, Retraction: cardiovascular disease, drug therapy, and mortality in Covid-19, N Engl J Med, doi:10.1056/NEJMoa2007621

Mehra, Ruschitzka, Patel, Retraction-hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet, doi:10.1016/S0140-6736%2820%2931324-6

Monteil, Kwon, Prado, Hagelkruys, Wimmer et al., Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2, Cell, doi:10.1016/j.cell.2020.04.004

Netea, Rovina, Akinosoglou, Antoniadou, Antonakos, Complex immune dysregulation in COVID-19 patients with severe respiratory failure, Cell Host Microbe, doi:10.1016/j.chom.2020.04.009

Rose-John, IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6, Int J Biol Sci, doi:10.7150/ijbs.4989

Savarino, Boelaert, Cassone, Majori, Cauda, Effects of chloroquine on viral infections: an old drug against today's diseases, Lancet Infect Dis, doi:10.1016/s1473-3099%2803%2900806-5

Sheahan, Sims, Leist, Scha ¨fer A, Won, Brown, Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV, Nat Commun, doi:10.1038/s41467-019-13940-6

Taiwan, Interim guidelines for clinical management of SARS-CoV-2 infection

Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomized controlled trial, BMJ, doi:10.1136/bmj.m1849

Vincent, Bergeron, Benjannet, Erickson, Rollin et al., Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol J, doi:10.1186/1743-422X-2-69

Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0

Yao, Ye, Zhang, Cui, Huang et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), Clin Infect Dis, doi:10.1093/cid/ciaa237

Zhang, Xu, Sun, Zhou, Current targeted therapeutics against COVID-19: based on first-line experience in China, Pharmacol Res, doi:10.1016/j.phrs.2020.104854

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0